10XREVIV

M42's IROS and 10XREVIV have announced a clinical study to evaluate precision nutrition approaches for people using GLP-1 medications. The research aims to assess how tailored nutrition plans can support patients on the weight-loss and diabetes drugs, a rapidly growing drug class. Details on study size, duration and locations were not disclosed in the announcement.